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Objective: Despite scientific evidence of effectiveness, psychotherapy for personality disorders is
not yet fully deployed, nor is its reimbursement self-evident. Both clinicians and health care
policy-makers increasingly rely on evidence-based medicine and health economics when
determining a treatment of choice and reimbursement. This article aims to contribute to that
understanding by applying these criteria on psychotherapy as a treatment for patients with
personality disorder.
Method: We have evaluated the available empirical evidence on effectiveness and
cost-effectiveness, and integrated this with necessity of treatment as a moderating factor.
Results: The effectiveness of psychotherapy for personality disorders is well documented with
favourable randomized trial results, 2 metaanalyses, and a Cochrane review. However, the evidence
does not yet fully live up to modern standards of evidence-based medicine and is mostly limited to
borderline and avoidant personality disorders. Data on cost-effectiveness suggest that psychotherapy
for personality disorders may lead to cost-savings. However, state-of-the-art cost-effectiveness data
are still scarce. An encouraging factor is that the available studies indicate that patients with
personality disorder experience a high burden of disease, stressing the necessity of treatment.
Conclusions: When applying an integrated vision on outcome, psychotherapy can be considered not
only an effective treatment for patients with personality disorder but also most likely a cost-effective
and necessary intervention. However, more state-of-the-art research is required before clinicians and
health care policy-makers can fully appreciate the benefits of psychotherapy for personality
disorders. Considerable progress is possible if researchers focus their efforts on evidence-based
medicine and cost-effectiveness research.
(Can J Psychiatry 2007;52:803–810)
Information on funding and support and author affiliations appears at the end of the article.
Clinical Implications
 From an effectiveness point of view, psychotherapy is the treatment of choice for personality disorders.
 The limited evidence about cost-effectiveness and necessity suggests that psychotherapy for personality
disorders is a cost-effective treatment for patients with a high burden of disease.
 To understand and influence health policy-making in mental health care successfully, clinicians need to
adopt an integrated perspective on effectiveness, cost-effectiveness, and necessity.
Limitations
 Some so-called effectiveness studies are in fact efficacy trials and most effectiveness research is limited
to borderline and avoidant personality disorders.
 The evidence on cost-effectiveness is limited to borderline personality disorder and involves
cost-minimization studies rather than state-of-the-art economic evaluations.
 The evidence on burden of disease is still scarce.
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During the last decade, research has shown that psycho-therapy is an effective treatment for patients with person-
ality disorder (for example1). Despite scientific evidence of
effectiveness, psychotherapy is not fully deployed in person-
ality disorders, nor is its reimbursement self-evident. In this
article, we argue that psychotherapy has the potential to be the
treatment of choice for people with personality disorder and
the potential to be valued highly by society if research and
practice work together to present more convincing evidence
to the medical field and the outside world.
Today, both clinicians and health care policy-makers increas-
ingly rely on evidence-based medicine and health economics
when determining a treatment of choice and reimburse-
ment.2,3 A possible explanation for the leeway of psychother-
apy in personality disorder could therefore be a mismatch of
the presented scientific evidence and modern standards of
evidence-based medicine and health economics. These mod-
ern standards not only focus on efficacy (Does this treatment
work in a well-controlled environment?) but also on the added
value and costs for patients and society. The status of psycho-
therapy as a valuable treatment for patients with personality
disorder will be endorsed if the psychotherapy field adopts
these modern standards.
Understanding of this reasoning by clinicians working with
patients with personality disorder is warranted for several rea-
sons. The first is that clinicians should be inspired to enhance
their level of clinical practice according to the modern
demands of evidence-based practice. A second reason is that
clinicians are held more and more responsible for managing
the scarce resources in health care as efficiently as possible to
deliver beneficial interventions to as many patients as possi-
ble.3 Notably in the development of practice guidelines, it is
important for clinicians to adopt modern quality standards,
otherwise the increasing number of treatment options in per-
sonality disorder would be associated with increasing medical
costs to be paid by society. One more reason to plea for the
adoption of new clinical quality norms is the strategic argu-
ment of professional autonomy: if clinicians ignore the recent
developments of evidence-based medicine and health eco-
nomics, the risk is that mental health care decisions are taken
by policy-makers alone and clinicians lose influence on
developments in their own professional field.
The reasons mentioned above provide the rationale to accu-
mulate and integrate empirical evidence and provide convinc-
ing arguments for the benefits of psychotherapy for
personality disorders. In pharmacy, such integration already
exists. In many countries the pharmaceutical industry has to
convince physicians and reimbursement authorities that their
medication is safe, effective, and cost-effective. Moreover,
reimbursement authorities may ask for evidence concerning
the necessity of the treatment. This quest for comprehensive
evidence in reimbursement issues is no longer limited to phar-
maceutics. It is becoming more and more accepted as the pre-
ferred route for implementation of all medical interventions.3
If we apply this line of reasoning to psychotherapy for person-
ality disorders, we have to create new standards of evaluation
to strengthen the position of psychotherapy. This article aims
to contribute to that understanding, by applying the criteria of
evidence-based medicine on psychotherapy as a treatment for
patients with personality disorder. We will do this by critically
analyzing the available empirical evidence on effectiveness
and cost-effectiveness, and combining this in an integrated
model with necessity of treatment as a moderating factor.
Empirical Evidence
Effectiveness
In evidence-based medicine, the highest level of evidence is
achieved when empirical studies, preferably randomized clin-
ical trials, can be combined in systematic literature reviews
and metaanalyses. The evidence on the effectiveness of psy-
chotherapy for personality disorders is evolving in that direc-
tion. In the last decade, 2 metaanalyses, 6 reviews, and 1
Cochrane review have been published.1,4–11
The available evidence clearly presents favourable results for
the effectiveness of psychotherapy for personality disorders,
notably borderline and avoidant personality disorders. The
first metaanalysis, published by Perry and colleagues,7 shows
that the effect size of psychotherapy for personality disorders
is 1.1 to 1.3, against 0.25 to 0.5 for various control conditions,
such as waiting lists or treatment as usual. This result is
encouraging, as an effect size of 0.8 or higher is considered
large.12 The authors also analyzed the relation between treat-
ment duration and recovery in 4 studies, and reported a strong
dose–effect relation. After 1.3 years of outpatient psychother-
apy (1 or 2 sessions per week), an average of 52% of patients
no longer met criteria for the diagnosis of personality dis-
order. By modelling both recovery with treatment and natural
recovery, they estimated that treatment is associated with up
to 7 times faster recovery than the natural course of personal-
ity disorder.7
The second metaanalysis1 describes the effects of cognitive-
behavioural therapy and psychodynamic therapy for person-
ality disorders and shows that both therapies lead to a signifi-
cant decrease of symptoms. The average effect size for
different outcome parameters is 1.5 for psychodynamic ther-
apy and 1.0 for cognitive-behavioural therapy. Of the patients
in psychodynamic therapy, 59% no longer met criteria for the
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diagnosis of personality disorder after treatment. In the
cognitive-behavioural therapy group, this figure was 47%.
The difference between these 2 results must be interpreted
with caution because the recovery figures are based on a small
number of studies and the 2 therapies are not easily compara-
ble, owing to different treatment durations. Nevertheless, an
important conclusion from this metaanalysis is that psycho-
therapy not only reduces psychiatric symptoms, it also has a
strong effect on personality pathology as well.1
Recent evidence seems to confirm the results of the
metaanalysis, showing that psychotherapy is a valuable treat-
ment for patients with personality disorder.13–21 Further,
Binks and colleagues11 published a Cochrane review on
psychosocial interventions for patients with borderline per-
sonality disorder, establishing the value of psychotherapy for
this patient group on the highest scientific level. Their evi-
dence suggests that with the help of psychosocial therapies
patients show improvement in self-harm and parasuicidal
behaviour, which are specific problem areas of borderline
personality disorder. The investigated therapies are still
experimental and the number of studies is still too small;
therefore, they concluded that their findings should be repli-
cated in larger real-world studies.11 Nevertheless, these
results are an important step in establishing a firm base of
knowledge for the effects of psychotherapy for personality
disorders.
Cost-Effectiveness
Although the evidence on cost-effectiveness of psychother-
apy for personality disorders is still limited, we can draw some
preliminary conclusions from the existing data. For instance,
several cost-benefit studies provide arguments in favour of
reimbursing psychotherapy for patients with personality dis-
order. For that particular patient population, these studies
indicate that psychotherapy can lead to significant reductions
in the use of other (mental) health care services and, therefore,
has the potential to reduce health care costs.22–26 For example,
Stevenson and Meares24 have shown that the costs for hospi-
talization in 30 patients with borderline personality disorder
are reduced significantly following outpatient psychotherapy
for 12 months. Their calculations indicate that psychotherapy
renders savings of $8433 per patient in the first year after
treatment. For 24 patients with personality disorder, Dolan
and colleagues25 showed that costs on psychiatric care and
imprisonment decrease after treatment. They even argued
that, if the patients’ recovery continue, the treatment costs of
psychotherapy would not only be paid back by the savings
achieved through therapy but also lead to additional savings
after 2 years. Gabbard and colleagues26 conducted a review of
the published evidence on costs and reductions through
psychotherapeutic treatment for personality disorders. They
concluded that the total direct medical costs of psychotherapy
are negative; accordingly, psychotherapy would not lead to
expenditures, but to savings.
The studies mentioned above mainly focused on direct (medi-
cal) costs. But psychotherapy for personality disorders can
also lead to a reduction in indirect costs, such as productivity
losses caused by absenteeism, for instance. There is evidence
to support this. Stevenson and Meares27 found that psycho-
therapy reduces absenteeism from work among patients with
personality disorder from an average of 4.7 to 1.4 months per
year. In a follow-up after 5 years, this reduction was still
evident.
A shortcoming of the studies published so far is that they can-
not be classified as formal cost-effectiveness analyses. A lot
of studies used tariffs as a proxy for costs instead of estimates
of the true (direct and indirect) costs. Moreover, costs are usu-
ally presented out of context and are not explicitly related to
the effects in a standardized cost-effectiveness ratio. How-
ever, this shortcoming does not necessarily jeopardize the evi-
dence that for severe personality disorders, especially
borderline personality disorder, psychotherapy saves medical
as well as work-related costs.
Discussion
Given the evidence regarding effectiveness and the
preliminary—but nevertheless favourable—cost estimates of
psychotherapy for personality disorders, the question arises,
Why the reluctance to fully deploy psychotherapy as a treat-
ment of choice for personality disorders and encourage its
reimbursement? We will discuss 3 important obstacles for
that deployment and ways to overcome them. The first obsta-
cle is the interaction between cost-effectiveness and (or)
effectiveness and necessity, which is not yet fully recognized
by the field. The second obstacle is the ongoing discussion
about necessity of treatment. The third obstacle consists of
still existing gaps in the evidence of effectiveness,
cost-effectiveness, and the assessment of necessity.
Necessity—The Missing Link Between Cost-Effectiveness
and Reimbursement
Cost-effectiveness and (or) effectiveness is often proclaimed
as the ultimate criterion for the value of a certain treatment,
but it is not the only important factor in the reimbursement dis-
cussion. It is a fact that not all cost-effective interventions are
reimbursed and some very expensive treatments with a low
effectiveness are nevertheless reimbursed. A stereotypical
example of this is the reluctance to reimburse Viagra with its
eminent cost-effectiveness ratio, while lung transplantation is
usually reimbursed in spite of high costs and low effective-
ness.28 Obviously, factors other than cost-effectiveness play
an important role in reimbursement policy. One of the identi-
fied factors is necessity of treatment. That is, the high need of
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patients assigned to lung transplantation actually gives rise to
favourable sentiments in the reimbursement decision process,
while the burden of erectile dysfunction in elderly men is not
considered decisive. This means we should appreciate evi-
dence about cost-effectiveness and necessity of treatment in a
broader perspective. This integrated perspective is well rec-
ognized in health economics and is called the equity debate. In
this equity debate, health economists discuss how efficiency
should be traded off with solidarity toward the patients most in
need, meaning a trade-off between cost-effectiveness and
necessity of treatment. One could take an egalitarian point of
view and argue that all resources should be allocated to
patients most in need. One could also take a utilitarian point of
view, arguing that health care resources should be spent effi-
ciently to do as much good as possible, meaning we should
spend the limited budget on interventions proven to be most
effective. In practice, most people take an in-between posi-
tion: we feel solidarity with patients most in need while at the
same time we feel that interventions should be distributed effi-
ciently. Consequently, if one proves that a treatment option
represents an efficient remedy for patients high in need,
chances for reimbursement increase. If our field were to pres-
ent such evidence convincingly, the status of psychotherapy
in personality disorder would be strengthened and
reimbursement would be facilitated.
Burden of Disease—The Missing Proof for Necessity of
Treatment
The necessity of treatment for patients in psychotherapy still
is a matter of debate. This is not just a popular belief. Even
health policy-makers and clinicians tend to refer to patients in
psychotherapy as YAVIS-patients. YAVIS is an acronym for
young, attractive, verbal, intelligent, and successful, labelling
patients who would benefit the most from psychotherapy. It is
a common idea that psychotherapists prefer to help
YAVIS-patients,29 that is, patients with a low burden of dis-
ease and thus a low necessity of treatment. Normally in health
care, a high burden of disease is associated with a greater need
for treatment—and more willingness to allocate financial
resources.30 Consequently, proving a high burden of disease
gives access to resources.
In the field of psychotherapy, efforts to contradict the YAVIS
assumption so far have failed. In general, studies use indica-
tors of suffering that are most often only meaningful inside
their own scientific community. Researchers in personality
disorders are tempted to choose outcome measures as ego
strength, defence style, and borderline personality disorder
severity. This may be meaningful within the field of personal-
ity disorders, but these concepts do not present a reference
point for comparing the suffering of personality disorder
patients to the suffering of somatic patients, for instance.
Whenever treatments for personality disorders are competing
for resources with treatments for somatic illnesses, the unde-
termined necessity of treatment pushes psychotherapy into a
defensive position.
What is needed are indicators of suffering in personality dis-
order that are widely accepted in health policy. Such an
unequivocal estimation of the necessity of treatment for per-
sonality disorders is only possible when measuring the burden
of disease with generic measures, focusing on quality of life.
Only then it is possible to relate the burden of disease of per-
sonality disorders to that of other mental and somatic dis-
orders. Among the first to choose this approach were the
investigators of the Dutch Standard Evaluation Project, who
used the generic EuroQol EQ-5D31 in a large sample of
patients admitted to specialized units providing psychother-
apy. This study shows that those patients having severe per-
sonality problems and disorders experience a high burden of
disease.32 A limitation of this study was the lack of standard-
ized diagnoses. However, the findings were replicated in a
large multicentre trial showing that the quality of life in
patients with standardized diagnoses of personality disorders
can be compared with the quality of life in patients with
chronic diseases such as rheumatic disease, Parkinson dis-
ease, or even lung cancer. The burden of having a personality
disorder was found to be even higher than in patients with type
II diabetes and HIV-infected patients.33 These results are also
in line with other studies showing that patients with personal-
ity disorder have a low global level of functioning.34–37 In one
of these studies, Skodol and colleagues35 compared
psychosocial functioning in patients with schizotypal, border-
line, avoidant, and obsessive–compulsive personality dis-
order to that of patients with mood disorder who have a global
level of functioning comparable to patients with chronic dis-
eases such as diabetes or arthritis.38,39 The results indicated
that patients with schizotypal or borderline personality dis-
order have even lower psychosocial functioning than patients
with mood disorder. In a general psychiatric population,
Nakao and colleagues34 reported a strong association between
the number of criteria from DSM-IV Axis II40 and the degree
of functional impairment (r = 0.60, P < 0.01). Moreover,
Verheul and colleagues41 showed that the relation between
personality pathology and global functioning is not (fully)
accounted for by Axis I comorbidity. Although these studies
used intermediate outcomes (such as psychological variables
instead of quality of life) to measure the burden of disease,
they suggest that personality disorders are indeed specifically
associated with a high burden of disease and, thus, a high
necessity of treatment.
Gaps in the Evidence—The Missing Research
The third obstacle is the existence of gaps in the integrated
evidence of effectiveness, cost-effectiveness, and necessity.
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Increasing the Quality Standards of Psychotherapy Research.
The favourable results presented by the reviews and
metaanalyses so far did not improve the deployment of psy-
chotherapy in personality disorders and its reimbursement.
One explanation is that the reviews discussed do not live up to
modern scientific standards, most notably Cochrane reviews.
Binks and colleagues11 recently conducted such a Cochrane
review and found preliminary but encouraging results for psy-
chotherapy in personality disorders. It should be noted that
most Cochrane reviews are extremely critical toward accepted
standards in medicine, as they rely heavily on high-quality
randomized trials, which are still scarce in long-term psycho-
therapy. Nevertheless, by introducing Cochrane standards in
the treatment of personality disorders, the authors set an
important trend. The investigation of Binks should be consid-
ered a sign of a maturing science. Such maturation will
strengthen the empirical base of psychotherapy and will
enhance its chances in guideline discussions and reimburse-
ment policy. It would be naive to assume that psychotherapy
will ever be fully deployed if the scientific and clinical com-
munity does not adopt modern scientific standards. To keep
the field of psychotherapy in line with the rest of the medical
world, high-quality effectiveness studies, covering the broad
spectrum of personality disorders, should be introduced
urgently.
From Efficacy to Effectiveness. When reporting results on the
effectiveness of psychotherapy, a critical remark has to be
made concerning the distinction between efficacy and effec-
tiveness.42 Many studies pretending to prove effectiveness of
psychotherapy are conducted with highly selected patients
and treatments in academic treatment settings and
well-trained and supervised therapists, making a generaliza-
tion of the results to the general patient population difficult. In
fact, these studies are efficacy studies, answering the ques-
tion, Does this treatment work in a well-controlled environ-
ment? However, in health care policy, the most important
question to be answered is, Does this treatment work in
everyday practice?43 This question can be answered by true
effectiveness studies, investigating the effect of interventions
done by ordinary practitioners, without extensive training and
supervision, given to ordinary patients usually seen in clinical
practice (for example20,44). In the aforementioned
metaanalyses, for example, this distinction is not clearly
made. While both efficacy and effectiveness studies are
important to strengthen the status of psychotherapy for
patients with personality disorder, there is a clear need of
well-designed effectiveness studies to demonstrate the value
of psychotherapy in regular clinical practice.
Dose–Effect Relations. In effectiveness research, much effort
is put into proving the superiority of one theoretical orienta-
tion over another. Despite all the effort and enthusiasm
involved, most of the time little difference is found between
psychotherapies from different theoretical orientations (for
example18). Typically, these results stem from research in
which treatment dosage (number of sessions or days of treat-
ment) is kept constant. But dosage in fact matters. Several
researchers have found a positive relation between treatment
duration (number of therapy sessions) and health improve-
ments or recovery of personality pathology.7,45,46 This was
confirmed by a randomized trial on the effectiveness of day
hospital treatment of borderline patients. Treatment results
take time. A clear reduction of symptoms and maladaptive
behaviour, as well as improved social functioning, did not
appear before 6 months of treatment.47 A significant reduction
of care requirement only appeared after 12 months of treat-
ment and the improvements grew over the course of an
18-month follow-up care period.48 These findings suggest
that more progress will be found in dose–effect studies than in
comparing rivalling theoretical orientations.
Sophisticated evidence about dose–effect relations in psycho-
therapy will give psychotherapists the evidence they need to
counter the modern trend of short therapies. Of course new
evidence has to be firm and has to include cost-effectiveness
research. High doses (and thus high costs) are not necessarily
a problem if a high dosage has a stronger effect. An example
of this approach is the study by Beecham and colleagues,49
showing a clear advantage of a step-down treatment program
compared to a fixed long-term inpatient stay. Nevertheless,
there is still much to be learned about dose–effect relations,
especially in inpatient and day hospital settings. This is impor-
tant because sound dose–effect data might serve as a powerful
argument to endorse psychotherapy for personality disorders.
Effective Ingredients of Psychotherapy. There are many forms
of therapy, all with their merits. Hence, the question is, What
makes each therapy work? This quest is comparable with the
search for the active substance in pharmacy. Despite the suc-
cess of the search for the active substance in our neighbouring
field of science, this knowledge gap still exists in
psychotherapy. One exception is the relationship between
therapist and patient, which is generally considered an estab-
lished, major determinant of the effect of psychotherapy.50
But next to relationship factors, there are other important
ingredients of psychotherapy that might be crucial. That is
why researchers get more and more interested in therapy fac-
tors such as degree of structure and clear focus of treatment,
coherence of therapeutic framework, and integration with
other patient services,4 as well as global principles of
change.51 If it would indeed be possible to identify the active
substance in psychotherapy, it might be possible to isolate it
from other—possibly expensive—components of therapy. As
such, the search for the effective factors in psychotherapy
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represents an effort to increase both effectiveness and
cost-effectiveness.
Formal Cost-Effectiveness Research. Formal cost-
effectiveness research explicitly studies the relation between
costs and effects. High costs of a treatment are not necessarily
a problem as long as the effects are substantial. In a literature
search, we identified promising book titles, such as Efficacy
and Cost-Effectiveness of Psychotherapy52 and Cost-
Effectiveness of Psychotherapy.53 However, these studies
present cost data but fail to establish a meaningful relation
between cost parameters and effects. It would be more justi-
fied to classify these studies as cost studies or cost-
minimization studies.
Recently, an extensive report was published in which the
available evidence on cost-effectiveness of psychological
therapies for borderline personality disorder, including dia-
lectical behaviour therapy, was reviewed systematically.54
The review team did an excellent job in performing separate
economic evaluations for the 6 randomized controlled trials
identified in their review of published studies. Cost-
effectiveness was assessed in terms of costs per avoided
parasuicide event (in all 6 trials) and costs per Quality
Adjusted Life Year (QALY)55 (in 4 of the 6 trials). The out-
come could not provide a convincing conclusion, owing to the
poor quality of the original studies, a mixture of methods to
assess outcome, and a doubtful generalizability. Neverthe-
less, the results suggest that such interventions have the poten-
tial to be cost-effective. The authors use the results of their
study to stress the need for high-quality cost-effectiveness
research in which a meaningful cost-effectiveness ratio can be
calculated, preferably in general terms such as costs per
QALY.
In addition, future cost-effectiveness research has to include
both direct and indirect costs caused by the illness and saved
by certain treatments. This is especially true for work-related
costs caused by educational delay, absenteeism, and
presenteeism, the latter describing the behaviour of people
who, despite serious complaints and ill health, still turn up at
their jobs.56 If formal cost-effectiveness studies of psycho-
therapy indeed show results comparable to already reim-
bursed treatments for somatic disorders, psychotherapists
would have a strong and formal argument to plea for
reimbursement of their therapy.
Proof of the Necessity of Treatment. We argued that generic
instruments measuring quality of life, such as the EuroQol
EQ-5D,31 are good choices as these instruments can compare
the suffering of patients with personality disorder with the
suffering of patients with well-known (somatic) illnesses. The
findings of Soeteman and colleagues32 must be seen as a first
effort to contradict the persistent belief that psychotherapy
patients experience a low burden of disease. We argue that
psychotherapists should challenge the YAVIS belief in a con-
vincing empirical way, otherwise the YAVIS sentiment will
jeopardize any claim for reimbursement of psychotherapy in
patients with personality disorder. Additional evidence using
quality of life assessments and standardized diagnoses are
needed to provide the decisive evidence.
Conclusion
Psychotherapy has the potential to develop into an evidence-
based field, broadly accepted and widely reimbursed health
discipline if innovative and comprehensive research on effec-
tiveness, cost-effectiveness, and necessity of treatment is ini-
tiated. By working closely together, research and practice can
provide efficient and equitable mental health care for patients
in need.
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Perspectives
Résumé : Renforcement du statut de la psychothérapie pour les troubles de la
personnalité : une perspective intégrée des effets et des coûts
Objectif : Malgré les données probantes scientifiques de son efficacité, la psychothérapie pour les
troubles de la personnalité n’est pas encore pleinement utilisée, et son remboursement ne va pas de
soi. Tant les cliniciens que les décideurs des soins de santé se fient de plus en plus à la médecine
fondée sur les données probantes et à l’économie de la santé pour déterminer un traitement de choix
et le remboursement. Cet article vise à contribuer à ce processus en appliquant ces critères à la
psychothérapie comme traitement pour les patients souffrant d’un trouble de la personnalité.
Méthode : Nous avons évalué les données probantes empiriques disponibles sur l’efficacité et la
rentabilité, et les avons intégrées avec la « nécessité de traitement » comme facteur modérateur.
Résultats : L’efficacité de la psychothérapie pour les troubles de la personnalité est bien
documentée par des résultats favorables d’essais randomisés, 2 méta-analyses, et une revue
Cochrane. Toutefois, les données probantes ne satisfont pas encore tout à fait aux normes modernes
de la médecine fondée sur les données probantes, et se limitent pour la plupart au trouble de la
personnalité limite et évitante. Les données sur la rentabilité suggèrent que la psychothérapie pour
les troubles de la personnalité pourrait entraîner des coûts réduits. Cependant, les données actuelles
sur la rentabilité sont encore rares. Un facteur encourageant est que les études disponibles indiquent
que les patients souffrant d’un trouble de la personnalité ont un fardeau élevé de maladies,
soulignant la nécessité d’un traitement.
Conclusions : Lorsqu’on applique une vision intégrée au résultat, la psychothérapie peut être
considérée non seulement comme un traitement efficace pour les patients souffrant d’un trouble de
la personnalité, mais aussi fort probablement comme une intervention rentable et nécessaire.
Cependant, il faut plus de recherche de pointe avant que les cliniciens et les décideurs des soins de
santé ne puissent pleinement apprécier les avantages de la psychothérapie pour les troubles de la
personnalité. Des progrès considérables sont possibles si les chercheurs concentrent leurs efforts sur
la médecine fondée sur les données probantes et la recherche sur la rentabilité.
